Revive Therapeutics Announces Extension of Proposed Private Placement
TORONTO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or…
Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need
~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse…
Halia Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
LEHI, Utah, Sept. 4, 2025 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage…
UPDATE — vTv Therapeutics to Participate in Upcoming September Investor Conferences
September 03, 2025 16:57 ET | Source: vTv Therapeutics Inc. HIGH POINT,…
Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock
September 02, 2025 21:33 ET | Source: Mineralys Therapeutics, Inc. RADNOR, Pa.,…
CHARM Therapeutics raises $80 million in Series B financing to advance development of best-in-class menin inhibitor for AML
New investors NEA and SR One lead round alongside existing investors OrbiMed,…
Rakovina Therapeutics Announces Three-Month Q2 ended June 30, 2025 Financial Results and Provides Corporate Update
All dollar amounts reflected in Canadian dollars unless otherwise stated August 28,…
Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock
August 27, 2025 20:53 ET | Source: Cognition Therapeutics, Inc. - The…
Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Operational Progress on September 4, 2025
Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Operational Progress…
Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer…
